Strategies to manage hepatitis C virus (HCV) disease burden
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10283782" target="_blank" >RIV/00216208:11110/14:10283782 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61383082:_____/14:#0000269 RIV/00216224:14110/14:00075456 RIV/65269705:_____/14:00062683 RIV/00023001:_____/14:00058938 RIV/75010330:_____/14:00010740
Výsledek na webu
<a href="http://dx.doi.org/10.1111/jvh.12249" target="_blank" >http://dx.doi.org/10.1111/jvh.12249</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/jvh.12249" target="_blank" >10.1111/jvh.12249</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Strategies to manage hepatitis C virus (HCV) disease burden
Popis výsledku v původním jazyce
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keepingthe number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden inthe countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%,this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus
Název v anglickém jazyce
Strategies to manage hepatitis C virus (HCV) disease burden
Popis výsledku anglicky
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keepingthe number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden inthe countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%,this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FE - Ostatní obory vnitřního lékařství
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Viral Hepatitis
ISSN
1352-0504
e-ISSN
—
Svazek periodika
21
Číslo periodika v rámci svazku
Supplement 1
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
30
Strana od-do
60-89
Kód UT WoS článku
000333893200004
EID výsledku v databázi Scopus
—